Agilent Asia Pacific’s Post

Interested in learning more about icIEF fractionation followed by mass spec? We have a webinar next week, on June 20th, with Lan Li from Amgen and Amreen Jonas from Mersana Therapeutics. You can use the link below to register. I am very excited about this one! #MassSpec

🔬 Discover the cutting-edge advancements in bi-specific antibody (#bsAb) therapeutics in GenScript's upcoming webinar. Learn about their diverse architectures and the innovative strategies used in their production. Bi-specific antibodies (bsAbs) target two different antigens or epitopes, showing great promise in enhancing drug efficacy. Optimizing bsAb purification is challenging due to their unique structures, but this webinar will provide valuable insights and solutions 🌟 The expert speaker, Rob Ford, will guide you through the various bsAb architectures and production strategies! 👉 Learn more and register here: https://buff.ly/3wBMlbY #DrugDevelopment #DrugDiscovery #CellTherapy #Biotherapeutics #MonoclonalAntibodies #MonoclonalAntibody #BasicResearch #BispecificAntibody

Join Dr. Lijuan Xu for a webinar on the transformative power of cell lines in biologics drug development! Learn how optimizing cell lines can speed up process validation and scale-up activities, leading to faster molecule movement into the clinic. We will showcase case studies of antibody drug production and how we've optimized vectors to diversify expression of polypeptide chains and shorten the turnaround time from transfection to primary cell banks generation to less than 8 weeks with titer of 10 g/L. Discover how PROBIO is working to reduce production costs and overcome obstacles that hinder the commercialization of antibody therapies. Don't miss out on this on-demand informative session! Webinar Link: https://hubs.la/Q02bjnw30

Catch up on a webinar, the Lumit™ FcRn Binding Immunoassay as a tool in the development of antibody-based therapeutics – Users share their experiences. Viewers will gain an understanding of Lumit™ Immunoassays, their applications, and how they simplify #FcRn binding analysis. https://bit.ly/3uTSIWK

Going to NBC? Be sure to check out Vera Bretton’s poster on Analytical Method Validation Strategy for Determination of Charge Heterogeneity of Antibody Therapeutics Using Reference Material Comparison as an Alternative to Spiking Studies. Learn more about our Antibody Analytical Capabilities here: https://lnkd.in/eQDcApdC #BioA, #Prolytix, #AAPS

If you are attending the National Biotechnology Conference next month in San Fran, be sure to check out Vera Bretton's poster on Analytical Method Validation Strategy for Determination of Charge Heterogeneity of Antibody Therapeutics Using Reference Material Comparison. Vera's expertise helps many clients navigate the research and development hurdles for biologics. Check out the link below to learn more about some of the projects her team supports here at Prolytix!

Today we announced groundbreaking enzymatic synthesis data at the #TIDESUSA annual meeting! Codexis has successfully synthesized a full-length, known siRNA oligonucleotide from starting material through the attachment of a conjugation moiety via an enzymatic route to support RNA-based therapeutics manufacturing. RNAi therapeutics key opinion leader John Maraganore noted, “The data presented today by Codexis are truly unprecedented—I believe this is the first enzymatic synthesis of a full-length oligonucleotide from starting material through the attachment of a conjugation moiety. This milestone provides meaningful proof of process to industry that there are alternative manufacturing methods available as the demand for RNAi therapeutics increases. The ECO Synthesis™ manufacturing platform has the potential to be a scalable and sustainable way to manufacture this important and growing new class of medicines.” Read our press release for more information: https://lnkd.in/d9WquAUY #enzymeengineering #proteinengineering #RNAi #RNAimanufacturing #enzymaticsynthesis

Yihan L., a Senior Scientist at AbbVie, walks us through her teams latest poster: "A Novel in vitro Serum Stability Assay for Antibody Therapeutics Incorporating Internal Standards." Yihan explains her team's innovative approach to pre-animal testing screening for biologics, focusing on stable molecule identification through precise incubation and LC-MS analysis. Discover how the use of internal standards, including NISTmAb and its Fc fragment, improve data accuracy and quality - promising findings that could transform biologics screening! https://bit.ly/3z7B1oK Rosendo Villafuerte-Vega, Hetal Sarvaiya #massspectrometry #glycosylation #oligonucleotides #vaccines #biotherapeutics #proteomics Dotmatics #biosimilars #cdmo

In recent times, the biopharmaceutical sector has seen a surge in the development of oligonucleotides for human medicine, serving both therapeutic and vaccine purposes. These oligonucleotides vary greatly in size and type, including small interfering RNAs (siRNA) and microRNA (miRNA), plasmid DNA (pDNA), as well as messenger RNA (mRNA) vaccines. Discover more about the complexities involved in the analytical testing of oligonucleotide products and the varying degrees of assistance offered by William Boomershine, Ph.D. through his latest whitepaper titled, Navigating the Analytical Complexity of Oligonucleotide Therapeutics ➡️https://gag.gl/n2bMIO #labservices #askalcami #alcami #oligonucleotide #analytical #CDMO

View the Full Video: https://buff.ly/499fCs4 - Across Monoclonal antibodies (mAbs), Antibody-drug conjugates (ADCs), Peptide-drug conjugates (PDCs), Oligonucleotides, Large or small molecule biomarkers or metabolites, Proteins and Peptides. We partner with clients evolving new modalities in large molecule bioanalysis as a provider of R&D solutions for today’s most promising biopharmaceuticals and biologics. Leverage our expertise in the evaluation of pharmacokinetics, efficacy, and safety at competitive cost and timeline. #BioDuroSundia #LargeMolecule #Bioanalysis #Antibody #Antibodies #Monoclonal #mAb #AntibodyDrug #ADC #PeptideDrug #PDC, #Oligonucleotide #Biomarker #Metabolite #Protein #Peptide